نتایج جستجو برای: paclitaxel

تعداد نتایج: 16677  

2017
Virginia M. Rosen Ines Guerra Mary McCormack Angélica Nogueira-Rodrigues Andre Sasse Veronica C. Munk Aijing Shang

OBJECTIVE Despite advances in cervical cancer prevention and diagnosis, outcomes for patients given a diagnosis of advanced and recurrent disease are poor. In the GOG240 trial, the addition of bevacizumab to paclitaxel-topotecan or paclitaxel-cisplatin has been shown to prolong survival compared with paclitaxel-topotecan or paclitaxel-cisplatin in patients with persistent, recurrent, or metasta...

Journal: :Journal of the National Cancer Institute 2011
Xiao-Feng Le Weiqun Mao Guangan He Francois-Xavier Claret Weiya Xia Ahmed Ashour Ahmed Mien-Chie Hung Zahid H Siddik Robert C Bast

BACKGROUND Less than 50% of ovarian cancers respond to paclitaxel. Effective strategies are needed to enhance paclitaxel sensitivity. METHODS A library of silencing RNAs (siRNAs) was used to identify kinases that regulate paclitaxel sensitivity in human ovarian cancer SKOv3 cells. The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian c...

2007
Ahmed Ashour Ahmed Anthony D. Mills Ashraf E.K. Ibrahim Jillian Temple Cherie Blenkiron Maria Vias Charlie E. Massie N. Gopalakrishna Iyer Adam McGeoch Robin Crawford Barbara Nicke Julian Downward Charles Swanton Stephen D. Bell Helena M. Earl Ronald A. Laskey Carlos Caldas James D. Brenton

The extracellular matrix (ECM) can induce chemotherapy resistance via AKT-mediated inhibition of apoptosis. Here, we show that loss of the ECM protein TGFBI (transforming growth factor beta induced) is sufficient to induce specific resistance to paclitaxel and mitotic spindle abnormalities in ovarian cancer cells. Paclitaxel-resistant cells treated with recombinant TGFBI protein show integrin-d...

Journal: :European review for medical and pharmacological sciences 2015
V Ercolak B Sahin M Gunaldi B B Duman C U Afsar

OBJECTIVE Kaposi sarcoma is an angioproliferative disease. Kaposi sarcoma is clinicopathologically classified into four subgroups based on epidemiological data. For its systemic treatment, in addition to some chemotherapeutics, taxanes have also been used during the recent years for their anti-angiogenic properties. In this study, we aimed to compare paclitaxel and non-paclitaxel chemotherapeut...

Journal: :The Journal of biological chemistry 2014
Shao-Rui Chen Lihong Zhu Hong Chen Lei Wen Geoffroy Laumet Hui-Lin Pan

Microtubule-stabilizing agents, such as paclitaxel (Taxol), are effective chemotherapy drugs for treating many cancers, and painful neuropathy is a major dose-limiting adverse effect. Cation-chloride cotransporters, such as Na(+)-K(+)-2Cl(-) cotransporter-1 (NKCC1) and K(+)-Cl(-) cotransporter-2 (KCC2), critically influence spinal synaptic inhibition by regulating intracellular chloride concent...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2003
E Marleen Kemper A Erik van Zandbergen Cindy Cleypool Henk A Mos Willem Boogerd Jos H Beijnen Olaf van Tellingen

P-Glycoprotein (Pgp) in the blood-brain barrier limits the uptake of substrate drugs into the brain. We have determined the efficacy of several (putative) inhibitors of Pgp (cyclosporin A, PSC833, GF120918, and Cremophor EL) on the penetration of paclitaxel into the mouse brain. Pgp inhibitors were administered p.o. before i.v. paclitaxel. Plasma and tissues were collected at 1, 4, 8, and 24 h ...

Journal: :International journal of oncology 2014
Jee-Eun Kim Min Ja Jang Dong-Hoon Jin Yoon Hee Chung Byung-Sun Choi Ga Bin Park Yeong Seok Kim Seonghan Kim Dae Young Hur Chien-Fu Hung Daejin Kim

Ovarian cancer has the highest mortality rate among gynecological malignancies due to high chemoresistance to the combination of platinum with taxane. Immunotherapy against ovarian cancer is a promising strategy to develop from animal-based cancer research. We investigated changes in the immunogenicity of paclitaxel-exposed ovarian cancer cells following exposure to other chemotherapeutic drugs...

2018
Md Sazzad Hassan Niranjan Awasthi Jun Li Fiona Williams Margaret A. Schwarz Roderich E. Schwarz Urs von Holzen

Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world and the overall 5 year survival rate of EAC is below 20%. Most patients with EAC present with locally advanced or widespread metastatic disease, where current treatment is largely ineffective. Therefore, new therapeutic approaches are urgently needed. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a no...

2015
Wei Liu Jun Gu Jun Qi Xiao-Ning Zeng Juan Ji Zheng-Zhen Chen Xiu-Lan Sun

Paclitaxel is generally used to treat cancers in clinic as an inhibitor of cell division. However, the acquired resistance in tumours limits its clinical efficacy. Therefore, the aim of this study was to detect whether co-treatment with lentinan enhanced the anti-cancer effects of paclitaxel in A549 cells. We found that the combination of paclitaxel and lentinan resulted in a significantly stro...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1999
B Kurdoglu N Cheong J Guan B W Corn W J Curran G Iliakis

Paclitaxel is a deterpene with antitumor activity against a variety of human neoplasms. Paclitaxel cytotoxicity is thought to derive mainly from a stabilization of microtubules as a result of enhanced tubulin polymerization that leads to an accumulation of cells in the mitotic (M) phase of the cell cycle. Because cells in this phase of the cell cycle are known to be radiosensitive, it was thoug...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید